BiotechTube
Home/REVOLUTION Medicines/James O. Buss, Ph.D.
JO

James O. Buss, Ph.D.

Chief Development Officer

REVOLUTION Medicines

Therapeutic Areas

Oncology

REVOLUTION Medicines Pipeline

DrugIndicationPhase
RMC-4630RAS-addicted cancers (SHP2 inhibitor)Phase 1/2
RMC-6236KRASG12X mutant solid tumors (Pan-RAS)Phase 1/2
RMC-6291KRASG12C mutant solid tumorsPhase 1/2
RMC-9805KRASG12D mutant solid tumorsPhase 1
RMC-8839KRASG13C mutant solid tumorsPhase 1

Leadership Team at REVOLUTION Medicines

MA
Mark A. Goldsmith, M.D., Ph.D.
President, Chief Executive Officer & Chairman
ZS
Zachary S. Hornby
Chief Operating Officer
MA
Margaret A. Hornbach
Chief Business Officer
SK
Steve Kelsey, M.D., FRCP, FRCPath
President, Research & Development
AL
Andrew L. Phillips, Ph.D.
Chief Scientific Officer
BA
Barbara A. Wood
Chief Legal Officer & Corporate Secretary
EM
Evan M. Kearns
Chief Accounting Officer
View full REVOLUTION Medicines profile